Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	€1.120	-1.75%	25,000
24/07/26	€1.140	0.00%	0
23/07/26	€1.140	0.00%	0
22/07/26	€1.140	-0.87%	25,000
21/07/26	€1.150	-0.86%	2,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Borsa Italiana Other stock markets 19:45:00 27/07/2026 +04			5-day change	1st Jan Change
1.120 ^EUR	0.00%		-3.45%	-23.81%

07-06	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN

Market Cap	9.54M 10.85M 8.88M 8.16M 15.32M 1.04B 15.52M 106M 41.24M 514M 40.75M 39.87M 1.78B	P/E 2024	30.8x	P/E 2025	17x
Enterprise Value	9.84M 11.19M 9.16M 8.41M 15.79M 1.07B 16M 109M 42.51M 530M 42.01M 41.1M 1.83B	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	18.98%	Yield 2024 *	-	Yield 2025	-

07-06	Laboratorio Erfo continues buyback, acquires 15,000 treasury shares	AN
06-29	Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares	AN
06-22	Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares	AN
06-20	Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired.	CI
06-15	Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares	AN
06-04	Equities trend higher; banks lead gains on the MIB	AN
05-22	European markets rebound; STM and Stellantis lead gains	AN
05-21	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
05-21	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
05-21	European markets set for lower open; focus on manufacturing PMIs	AN
04-20	Brent rebounds; futures signal risk-off sentiment	AN
04-17	Greenlight on Hormuz sparks global equity rally	AN
04-13	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

04-09	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/10/25	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/08/25	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/06/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/05/25	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Stock

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

07-06	Laboratorio Erfo prosegue buyback e rileva 15.000 azioni proprie
06-29	Laboratorio Farmaceutico Erfo rileva 14.000 azioni proprie
06-22	Erfo prosegue coi buyback e riacquista 28.000 azioni
06-15	Laboratorio Farmaceutico Erfo acquista 15.000 azioni proprie
06-04	Borse rialziste; bene i bancari sul MIB

1 week	-3.45%
Current month	-5.08%
1 month	-3.03%
3 months	-11.11%
6 months	-18.25%
Current year	-23.81%

1 week	1.1	1.14
1 month	1.1	1.26
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	56	01/01/2013
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	56	01/01/2013
Flavio Corpina BRD	Director/Board Member	47	01/01/2017
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/12/25	Alessandro Cutè	Sell	Chief Executive Officer	322,000	3.5778%
16/12/25	Alessandro Cutè	Sell	Chief Executive Officer	968,000	10.7556%
29/06/22	Alessandro Cutè	Others	Chief Executive Officer	300,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	0.00%	-3.45%	-12.50%	+12.00%	11.06M
ELI LILLY AND COMPANY	+0.13%	+4.41%	+47.35%	+163.20%	1,067B
JOHNSON & JOHNSON	+0.97%	+6.88%	+58.02%	+53.12%	635B
ABBVIE INC.	-0.94%	+1.39%	+35.02%	+72.60%	458B
ROCHE HOLDING AG	+1.41%	+8.56%	+38.93%	+32.17%	347B
NOVARTIS AG	+1.28%	+4.40%	+38.42%	+41.62%	295B
ASTRAZENECA PLC	+1.72%	+4.10%	+19.31%	+20.45%	262B
NOVO NORDISK A/S	+1.84%	-0.46%	-27.78%	-38.65%	216B
AMGEN INC.	+0.06%	+3.32%	+22.73%	+59.40%	203B
GILEAD SCIENCES, INC.	+0.94%	-2.02%	+12.32%	+70.59%	161B
Average	+0.74%	+1.39%	+23.18%	+48.65%	364.35B
Weighted average by Cap.	+0.60%	+2.25%	+36.75%	+78.19%

	2024	2025
Net sales	6.03M 6.86M 5.62M 5.16M 9.68M 658M 9.81M 66.75M 26.07M 325M 25.76M 25.2M 1.12B	9.73M 11.07M 9.06M 8.32M 15.62M 1.06B 15.83M 108M 42.05M 524M 41.56M 40.66M 1.81B
Net income	353K 401K 328K 302K 566K 38.49M 574K 3.9M 1.52M 19M 1.51M 1.47M 65.69M	737K 838K 686K 630K 1.18M 80.39M 1.2M 8.15M 3.18M 39.7M 3.15M 3.08M 137M
Net Debt	5.77K 6.56K 5.37K 4.93K 9.26K 629K 9.38K 63.81K 24.92K 311K 24.63K 24.1K 1.07M	295K 336K 275K 253K 474K 32.23M 480K 3.27M 1.28M 15.91M 1.26M 1.23M 55M